ArriVent BioPharma, Inc. AVBP Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$145.24M+12.7% | -$166.31M-9.8% | -$151.4M-10.5% | -$136.98M-7.5% | -$127.46M-58.4% | ||
| -$2.83M+6.5% | -$3.03M— | —— | —— | —— | ||
| $15.73M+25.7% | $12.52M+22.1% | $10.25M+38.5% | $7.4M+52.5% | $4.85M+51.3% | ||
| —— | —— | —— | —— | $205K+127% | ||
| $7.72M+15.8% | $6.67M+28.0% | $5.21M-29.1% | $7.34M+198% | $2.46M-61.4% | ||
| $13.81M+7.6% | $12.84M+12.5% | $11.41M+147% | $4.62M+1,313% | -$381K+74.0% | ||
| $30K+243% | -$21K-5.0% | -$20K— | —— | —— | ||
| -$134.47M+16.3% | -$160.59M-9.9% | -$146.08M-15.4% | -$126.63M-5.9% | -$119.59M-70.3% | ||
| $327.5M+20.0% | $272.93M+60.3% | $170.3M+32.6% | $128.47M-17.4% | $155.44M-19.9% | ||
| $223.03M+10.6% | $201.71M+65.1% | $122.15M+47.2% | $82.97M+73.2% | $47.91M+2,720% | ||
| -$104.47M-46.7% | -$71.23M-47.9% | -$48.15M-5.8% | -$45.5M+57.7% | -$107.53M+44.1% | ||
| $256.99M+23.1% | $208.78M— | —— | —— | —— | ||
| $251.18M+23.7% | $203.06M+20.6% | $168.39M+104% | $82.46M+970% | $7.71M-95.9% | ||
| $12.24M+143% | -$28.75M+83.1% | -$170.18M— | —— | —— | ||
| —— | —— | —— | —— | $205K+127% | ||
| $30K+243% | -$21K-5.0% | -$20K— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $13.81M+7.6% | $12.84M+12.5% | $11.41M+147% | $4.62M+1,313% | -$381K+74.0% | ||
| $223.03M+10.6% | $201.71M+65.1% | $122.15M+47.2% | $82.97M+73.2% | $47.91M+2,720% | ||
| —— | —— | —— | —— | —— | ||
| $30K+243% | -$21K-5.0% | -$20K— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ArriVent BioPharma, Inc. generate?
- ArriVent BioPharma, Inc. (AVBP) generated -$134.5M in operating cash flow over the trailing twelve months.
- Where does ArriVent BioPharma, Inc.'s cash flow data come from?
- Every line is extracted from ArriVent BioPharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.